USP’s Medicine Supply Map - the first of its kind in the world - enhances visibility into the upstream medicines supply chain to help governments, manufacturers, distributors, and providers identify and address vulnerabilities, lessen quality risks, reduce the frequency and duration of potential drug shortages, and protect patients.
“USP’s Medicine Supply Map is an early-warning system for possible drug shortages, whether due to global health crises, natural disasters, geopolitical events, or quality-related issues in manufacturing.”- Vimala Raghavendran, Senior Director, USP Pharmaceutical Supply Chain Center
Policymakers are increasingly focused on addressing risks and vulnerabilities in pandemic preparedness infrastructure. The Medicine Supply Map leverages insights derived from the use of USP quality standards in more than 22 thousand locations around the world, spanning 92 percent of generic medicines approved in the U.S. It aggregates more than 40 external datasets and 250 million data points to quantify risk and resilience in the upstream pharmaceutical supply chain.
The Medicine Supply Map provides insights on supply chain vulnerabilities to drive decision-making.
Pinpoint supply chain risks
Leveraging multiple data sources, the Medicine Supply Map helps identify, characterize, and quantify risk factors to help guard against over-reliance on over-concentrated sources, reduce disruptions, and build resilience.